2Vernhet L,Allain N,Payen L,et al. Resistance of human mullidrug resistance-associated protein 1 overexpressing lung tumor cells to the anticancer drug arsenic trioxide [J]. Biocheical Pharmacology, 2001,61 (7) : 1387.
3Vernhel L,Seile MP,Allain N,et al. Arsenic induces expression of the multidrug resistance associated protein 2 (MRP2) gene in primary rat and human hepatocytes[J]. J Pharmacol Exp Ther,2001,298(1) :234.
4Yang CH, Kuo ML,Chen JC, et al. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells[J], Br J Cancer, 1999,81 (5) :796.
5Liu J,Chen H, Miller DS,et al. Overexpression of glutathione S-transferase Ⅱ and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic[J]. Mol Pharmacol, 2001,60 ( 2 ): 302.
6Boucheix C, Benoit P, Frachet P, et al. Molecular cloning of the CD9 antigen. A new family of cell surface proteins[J]. J Biol Chem, 1991, 266(1):117-122.
7Ikeyama S, Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA[J]. J Exp Med, 1993, 177(13):1231-1237.
8Higashiyama M, Doi O, Kodama K, et al. Immunohistochemically detected expression of motility-related protein-1(MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis[J]. Int J Cancer, 1997, 74(2):205-211.
9Huang CI, Kohno N, Ogawa E, et al. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients[J]. Am J Pathol, 1998, 153(3):973-983.
10Miyake M, Nakano K, Itoi SI, et al. Motility-related protein-1(MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer[J]. Cancer Res, 1996, 56(6):1244-1249.
3Kumar S, Hammersehlag M R. Acute respiratory infection due to Chlamydia pneumoniae : current status of diagnostic methods [ J ]. Clin Infect Dis,2007,44(4) :568-576.
4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteen informational sup- plement [ S ]. USA : CISI,2008.
5Brodniewicz T,Grynkiewicz G. Preclinical drug development [ J ]. Acta Pol Pharm ,2010,67 (6) :578-585.
6Paraiu A, Homorodean D,Jodal A,et al. Respiratory features of As- pergillus infection in eight years of pulmonology practice [J].Prveumologia ,2010,59 (4) : 204-207,209-210.
7Theerawit P,Vongsoasup A, Kiatboonsri S. Identifying culous mycobacterium lung diseases in acid-fast bacilli positive patients [ J ]. Southeast Asian J Trop Med Public Health, 2010,1 (6) :1432-1437.
8Rozzini R,Trabucchi M. Pneumonia and mortality beyond hospital discharge in elderly patients [ J ]. Chest,2011,139 ( 2 ) :473-474.
9Pedersen J M, Matsson P, Bergstrm C A S, et al. Prediction and identification of drag interactions with the human ATP-bind- ing cassette transporter muhidmg-resistance associated protein 2( MRP2 ; ABCC2) [J]. J Med Chem, 2008, 51 ( 11 ) : 3275.
10Van Zanden J J, Wortelboer H M, Bijlsma S, et aL Quantitative structure activity relationship studies on the flavonoid mediated inhibition of muhidrug resistance proteins 1 and 2 [ J ]. Biochem Pharm, 2005, 69 (4) : 699.
